{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 136 of 169', 'Appendix 4G: Financial disclosure', 'Investigators will provide LEO with sufficient, accurate financial information as requested to', 'allow LEO to submit complete and accurate financial certification or disclosure statements to', 'the appropriate regulatory authorities. Investigators are responsible for providing information', 'on financial interests during the course of the clinical trial and for 1 year after completion of', 'the clinical trial, or for a longer period of time if required by local legislation.', 'Appendix 4H: Committee structure', 'Patient safety will be carefully assessed by an independent Data Monitoring Committee', '(DMC). All members will be independent of the trial (i.e. they will not be participating', 'investigators or employees at participating sites) and of LEO (i.e. they will not be LEO', 'employees). The DMC members are experienced with clinical trials and will be responsible', 'for assessing the safety of the subjects through assessment of the safety of the treatment', 'regimen during the trial and through monitoring the overall conduct of the trial. Refer to', 'Appendix 8 for a list of trial committee members.', 'The DMC will review data on a regular basis. Additional meetings may also be called on an', 'ad hoc basis, as requested by the DMC or LEO. All data collected at the time of the data cut-', 'off/scheduled meetings will be included in the summaries for the DMC, including data from', 'subjects still ongoing in the trial. The DMC will examine summaries and listings of AEs,', 'specific laboratory parameters and subject disposition data as detailed in the DMC Charter.', 'Full details of the analyses to be presented to the DMC will be specified in a separate DMC', 'statistical analysis plan.', 'The DMC will have an independent statistician and an independent administrator who will', 'remain independent of the trial management team.', 'The chairman of the DMC, in conjunction with the other members, will communicate their', \"recommendations to LEO's clinical project manager after each meeting. The chairman of the\", 'DMC will provide written reports to LEO after each formal review to indicate the', \"committee's recommendation regarding safety concerns and trial continuation. Further details\", 'on all aspects relating to the DMC are provided in the DMC charter.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 137 of 169', 'Appendix 4I: Trial and site closure', 'Premature termination of trial or trial site', 'LEO, the investigator, the IRB/IECs or competent authorities may decide to stop the clinical', 'trial, part of the trial or a trial site at any time, but agreement on procedures to be followed', 'must be obtained.', 'If a clinical trial is suspended or prematurely terminated, the investigator must inform the', 'subjects promptly and ensure appropriate therapy and follow-up. As specified by applicable', 'regulatory requirements, the investigator or LEO must promptly inform IRB/IECs and', 'provide a detailed written explanation. Relevant competent authorities must be informed.', 'The trial must be terminated if the perception of the benefit/risk ratio (judged from clinical', 'signs and symptoms, (S)AEs and/or remarkable safety laboratory changes) becomes', 'unfavourable for the continuation of the trial.', 'Reasons for the early closure of a trial site by LEO or investigator may include but are not', 'limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', \"IRB/IEC or local health authorities, LEO's procedures, or GCP guidelines.\", 'Inadequate recruitment of subjects by the investigator.', 'Discontinuation of further IMP development.', 'Completion of trial', 'Investigators will be informed when subject recruitment is to cease. Trial enrolment will be', 'stopped at a trial site when the total requested number of subjects for the clinical trial has', \"been obtained, irrespective of the specific site's planned inclusion number.\", 'Trial sites will be closed upon trial completion. LEO will undertake arrangements for the', 'collection and disposal of any unused trial material that the investigator is not required to', 'keep in his/her files. A trial site is considered closed when all required documents and trial', 'supplies have been collected and a trial site closure visit has been performed.', 'When the randomisation code has been broken, the investigators will receive information', 'about the treatment allocation for the subjects randomised at their respective sites and will be', \"asked to record this in the subject's medical record.\", 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}